Roth Capital raised the firm’s price target on Electrovaya (ELVA) to $10 from $7 and keeps a Buy rating on the shares. The commissioning of cell production at Electrovaya’s Jamestown, NY, facility towards the end of calendar 2026 will likely be a transformational moment for the company, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVA:
- Electrovaya Posts Strong Q1, Boosts Cash as It Ramps Next-Gen Battery Push
- Electrovaya reports Q1 EPS 2c, consensus 1c
- Electrovaya sees FY26 revenue over $83M, consensus $84.26M
- ELVA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Electrovaya Sets February 12 Date for Q1 2026 Results and Investor Call